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Abstract
The survival of the Tasmanian devil (Sarcophilus harrisii) is threatened by devil facial tumour
disease (DFTD). This transmissible cancer is usually fatal, and no successful treatments
have been developed. In human studies, the small immunomodulatory molecule imiquimod
is a successful immunotherapy, activating anti-tumour immunity via stimulation of toll-like
receptor-7 (TLR7) signaling pathways. In addition, imiquimod is a potent inducer of apopto-
sis in human tumour cell lines via TLR7 independent mechanisms. Here we investigate the
potential of imiquimod as a DFTD therapy through analysis of treated DFTD cell lines and
Tasmanian devil fibroblasts. WST-8 proliferation assays and annexin V apoptosis assays
were performed to monitor apoptosis, and changes to the expression of pro- and anti-apo-
ptotic genes were analysed using qRT-PCR. Our results show that DFTD cell lines, but not
Tasmanian devil fibroblasts, are sensitive to imiquimod-induced apoptosis in a time and
concentration dependent manner. Induction of apoptosis was accompanied by down-regu-
lation of the anti-apoptotic BCL2 and BCLXL genes, and up-regulation of the pro-apoptotic
BIM gene. Continuous imiquimod treatment was required for these effects to occur. These
results demonstrate that imiquimod can deregulate DFTD cell growth and survival in direct
and targeted manner. In vivo, this may increase DFTD vulnerability to imiquimod-induced
TLR7-mediated immune responses. Our findings have improved the current knowledge of
imiquimod action in tumour cells for application to both DFTD and human cancer therapy.
Introduction
The immunotherapeutic agent imiquimod (R-837) is a synthetic guanosine analogue recog-
nised for its immune-stimulating capabilities. As an agonist of the single stranded RNA pat-
tern recognition receptor toll-like receptor-7 (TLR7), imiquimod promotes potent anti-viral
innate immunity and T helper-1 (TH1) type adaptive responses via activation of plasmacytoid
dendritic cells, myeloid dendritic cells and macrophages [1–5]. TLR7 signaling in these cells
stimulates nuclear factor kappa-B (NFκB) and interferon regulatory factor (IRF) pathways,
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leading to enhanced expression of genes required for antigen presentation and immune
stimulation [1–4, 6]. As an immunotherapeutic agent, imiquimod has shown activity against
epithelial and cutaneous pre-neoplastic, neoplastic and metastatic lesions [7]. Large-scale
inflammatory infiltration and initiation of cytotoxicity are characteristic of a successful imiqui-
mod treatment, and full lesion regression is common [8–11]. FDA approval was granted for
the topical treatment of genital and perianal warts with imiquimod in 1997, and superficial
basal cell carcinoma and actinic keratosis in 2004 [7].
The activation of tumour-specific TH1 responses during imiquimod immunotherapy is
associated with tumour regression [8, 9, 12]. In addition, cell culture studies have demon-
strated direct activation of tumour cell apoptosis and autophagy in response to imiquimod
treatment [13–17]. Imiquimod exerts these effects in a tumour specific manner, independently
of both TLR7 signaling and immune cell function [13, 15, 18, 19]. Pro- and anti-apoptotic pro-
teins, such as Noxa, BCL2 and MCL1, are involved in the regulation of these apoptotic path-
ways, and more recently both oxidative and endoplasmic reticulum (ER) stress pathways have
also been implicated [14, 18–21]. The impact of these molecular changes on the efficacy of imi-
quimod immunotherapy remains undefined.
Devil facial tumour disease (DFTD) describes two genetically distinct transmissible
tumours threatening wild populations of Tasmania’s largest extant marsupial, the Tasmanian
devil (Sarcophilus harrisii) [22]. Initially observed in 1996, the first of the tumours (DFT1) is of
Schwann cell origin, and has caused severe population declines across most of the devil’s natu-
ral habitat [23–25]. In comparison, the newer tumour (DFT2) was discovered in 2014, is of
unknown origin, and is currently localised to a small region of South-Eastern Tasmania [22].
Both DFT1 and DFT2 are somatic cell lineages transmitted as allografts due to a lack of recog-
nition by the devil’s immune system [22, 26, 27]. With little natural immunity against the
tumour cells, developing successful therapies and vaccinations against these cancers has
proven to be challenging [27–29]. An immunotherapy against DFTD, although challenging to
distribute among a wild devil population, could break immune tolerance against the tumour
and may promote long-term immunity against the disease. Investigation of these mechanisms
may also reveal new techniques for the development of a prophylactic DFTD vaccine.
Previously, we demonstrated that Tasmanian devil mononuclear cells (MNCs) express
functional TLR7. As with many human tumour cell lines, we also found that DFT1 cells in cul-
ture underwent apoptosis after imiquimod treatment [30]. Taken together these data suggest
that imiquimod has potential as a DFTD immunotherapy. Here we report a more detailed
analysis of the response of DFTD cultures to imiquimod treatment. These data will enable a
greater understanding of imiquimod induced tumour cell death for application to both DFTD
and human cancer therapy.
Methods
Cell culture
DFT1 cell lines C5065, 1426, 4906 and ½Pea were provided by A-M. Pearse and K. Swift of the
Tasmanian Department of Primary Industries, Parks, Water and Environment (DPIPWE).
These cell lines were previously established from DFT1 biopsies obtained under the approval
of the Animal Ethics Committee of the Tasmanian Parks and Wildlife Service (permit num-
bers 33/2004-5 and 32/2005-6). The DFT2 cell line RV was established from a DFT2 biopsy
and the fibroblast cell line TD344 was established from a Tasmanian devil tissue biopsy (per-
mit numbers A0012513 and A0014976). Stocks stored in liquid nitrogen were thawed when
required and cultured in RPMI medium (GIBCO, New York, USA) supplemented with 10%
heat-inactivated foetal calf serum (FCS) (GIBCO, New York, USA), 1% GlutaMAXTM
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(GIBCO, New York, USA) and 1% Antibiotic Antimycotic (GIBCO, New York, USA) (RPMI/
10FCS). DFT2 and fibroblast cell lines were cultured in RPMI/10FCS supplemented with 10%
AminoMAXTM-II Complete Medium (GIBCO, New York, USA). The cultures were main-
tained at 35˚C in a humidified 5% CO2 incubator. When required for experimentation, DFTD
cells were gently flushed from their culture surface using RPMI/10FCS. Adherent fibroblasts
were washed in phosphate buffered saline (PBS) and removed from their surface with 0.025%
Trypsin-EDTA (GIBCO, New York, USA) at 37˚C for 2 minutes. RPMI/10FCS was added to
inhibit the trypsin. Cells were pelleted by centrifugation at 500 g for 5 min. Cell viability counts
were performed on an improved neubauer haemocytometer by trypan blue dye exclusion.
Imiquimod stimulation
Imiquimod (AdipoGen, San Diego, USA) was dissolved in dimethyl sulfoxide (DMSO) and
diluted to working concentrations with sterilised water or RPMI/10FCS. Unless otherwise
stated, cell cultures were stimulated with imiquimod at 60 μg/ml (0.5% DMSO). Vehicle con-
trols were treated with DMSO at concentrations equivalent to experimental cultures. Stimu-
lated cultures were maintained at 35˚C in a humidified 5% CO2 incubator for the treatment
duration. Cell lines ‘pulsed’ with imiquimod were treated for 24 or 48 h, washed three times in
sterile PBS, and re-cultured in RPMI/10FCS without imiquimod treatment for the remainder
of the experiment (pulsed cells).
Cell proliferation analysis (WST-8 Assay)
The DFT1 cell lines C5065, 1426 and 4906, the DFT2 cell line RV and the non-transformed
fibroblast cell line TD344 were seeded into flat-bottom 96-well cell culture plates at a concen-
tration of 1x105 cells/ml in 100 μl of RPMI/10FCS. Cells were treated in triplicate with imiqui-
mod at 7.5, 15.0, 30.0, 60.0 or 120.0 μg/ml for 0, 12, 24, 48, 72, 96 or 120 h. Relative cell
number in culture was analysed using the Cell Counting Kit-8 (WST-8) (Sigma-Aldrich, St
Louis, USA) according to the manufacturer’s instructions. Absorbance was measured at
OD570-OD650 using the SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale,
USA). Baseline metabolic rate was determined by absorbance at the 0 h time point. Changes to
cell number were calculated relative to untreated cultures.
Annexin V cell death assay
The DFT1 cell line C5065 and DFT2 cell line RV were seeded into 24-well cell culture plates at
a concentration of 1x105 cells/ml in 500 μl of RPMI/10FCS. Cells were treated with imiquimod
for 8, 16, 24, 48, 72, 96 or 120 h. Analysis of cell death was performed using the Annexin V cell
death assay (BD Pharmingen, San Diego, USA), as previously described [30]. Samples were
analysed on the FACSCantoTM II Flow Cytometer (BD Biosciences, San Jose, USA). Kaluza1
Flow Analysis Software (Beckman Coulter, Pasadena, USA) was used to calculate the percent-
age of cells positive for annexin V and propidium iodide (PI). Viable cells were negative for
both annexin V and PI staining, necrotic cells were positive for PI staining, early apoptotic
cells were positive for annexin V staining, and late apoptotic cells were positive for both
annexin V and PI staining.
Cell cycle analysis
The DFT1 cell line C5065, the DFT2 cell line RV and the fibroblast cell line TD344 were seeded
into 24-well culture plates at a concentration of 1x105 cells/ml in 500 μl of RPMI/10FCS. Cells
were treated with imiquimod for 48 h. Cell cycle analysis was performed according to the
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methods of Riccardi and Nicoletti [31], as previously described [30]. PI staining was analysed
by flow cytometry using the FACSCantoTM II flow cytometer. The Kaluza1 Flow Analysis
Software was used to compile histograms and measure hypodiploid and diploid peaks. A hypo-
diploid peak represents DNA fragmentation and suggests that apoptotic cells are present.
Tasmanian devils and biological samples
Primary tissue samples were obtained from Tasmanian devils with the approval of the Univer-
sity of Tasmania Animal Ethics Committee (permit numbers A0012513 and A0014976). Devils
were anaesthetized with isofluorane gas in oxygen at a rate of 2 L/minute and approximately
10 ml of blood was obtained from the jugular vein as previously described [32]. Blood was
transported in lithium heparin anticoagulant tubes (Greiner Bio-One, Kremsmunster, Austria)
at room temperature and processed within 24 h of collection. Peripheral blood mononuclear
cells (PBMNCs) were isolated using density gradient centrifugation on Histopaque-1077
(Sigma-Aldrich, St Louis, USA), according to the manufacturer’s instructions. DFTD biopsies
were collected from diseased wild devils using a 4 mm disposable biopsy punch (Kai Medical,
Solingen, Germany). Peripheral nerve samples were collected from the brachial plexus or sci-
atic nerve of euthanised Tasmanian devils. Tumour biopsies and peripheral nerve samples
were immediately placed in RNAlater and transported on ice. Samples were homogenized in
TriReagent (Sigma-Aldrich, St Louis, USA) with a Mini Beadbeater-24 (BioSpec Products,
Bartlesville, USA) and 2.0 mm Zirconia Beads (BioSpec Products, Bartlesville, USA).
RNA extraction and cDNA preparation
Cell lines and biological samples were lysed in 1 ml of TriReagent and RNA was extracted
according to the manufacturer’s instructions. RNA was suspended in TE buffer (pH 8.0)
(Ambion, Austin, USA) and DNase treated with the TURBO DNA-freeTM kit (Ambion, Aus-
tin, USA). The concentration and purity of the RNA was assessed using a NanoDrop 1000
Spectrophotometer (NanoDrop Technologies, Wilmington, USA). Samples with an A260/
A280 ratio of greater than 1.8 were selected and 0.5–1.0 μg of total RNA was reverse tran-
scribed to cDNA using the GoScriptTM Reverse Transcription System (Promega, Madison,
USA). A non-reverse transcribed control (no-RT control) was included to identify the pres-
ence of any contaminating genomic DNA.
Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR)
Primer sequences were designed for target genes identified in the Tasmanian devil reference
genome Devil7.0 assembly GCA_000189315.1, using the NCBI PrimerBLAST tool (Table 1).
Primers were synthesized by GeneWorks (Adelaide, Australia). qRT-PCR was performed using
the LightCycler1 480 SYBR Green I Master (Roche, Indianapolis, USA) and LightCycler1 480
(Roche, Indianapolis, USA), as previously described [30]. Expression of 18S rRNA was mea-
sured as reference gene, and no-template controls and no-RT controls were included in all anal-
yses. Standard curves were performed for validation of reaction efficiency, and the comparative
Ct method was used for calculation of expression fold change [33]. Statistical significance was
calculated from log2-converted values using a repeated measures one-way ANOVA and a Dun-
nett’s multiple comparisons test. Statistical significance was defined as  =<0.05,  =<0.01,
 =<0.001.
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Agarose gel electrophoresis
qPCR products were visualized on 1.5% agarose gels by electrophoresis for 40 min at 100 V. A
Quick-Load 100 base-pair DNA ladder (New England Biolabs, Ipswich, USA) was included
for determination of PCR product length. Photographs of gels were taken with a Carestream
Image Station 4000 MM (Carestream, Toronto, Canada).
Results
Imiquimod reduces DFT1 and DFT2 cell number in a time and
concentration dependent manner
Previous studies show that the immunotherapeutic agent imiquimod induces apoptosis in a
range of tumour cell lines, including the DFT1 cell line C5065 [15, 16, 30, 34]. To investigate
the effects of imiquimod more thoroughly, we analysed DFT1 cell lines (C5065, 1426, 4906)
and a DFT2 cell line (RV) after treatment in culture. We first examined the effects of imiqui-
mod using a WST-8 proliferation assay, which measures metabolic activity as an approxima-
tion of relative cell number in culture. Our data showed that continuous imiquimod treatment
decreased DFT1 and DFT2 cell number in a concentration and time dependent manner. High
imiquimod concentrations were required to reduce DFTD cell number, with lower concentra-
tions increasing cell number in several cultures (Fig 1A). This increase is likely an artifact of
decreased metabolic activity in untreated cultures as a result of overcrowding, as it was not
detected at an end-point of 24 h (Fig 1B). At a high imiquimod concentration (60 μg/ml), cell
number decreased gradually over a 120 h time period (Fig 1C). All DFTD cultures were sensi-
tive to this change, but responded at different rates, with the DFT2 cell line RV demonstrating
the most rapid reduction. The rates at which DFTD cell lines responded to imiquimod treat-
ment correlated with their baseline metabolic rate, which was highest in RV cultures, moderate
in C5065 cultures and lowest in 1426 and 4906 cultures (Fig 1D). Reductions in cell number
were not maintained after pulsing of DFT1 cells with high concentrations of imiquimod for 24
or 48 h, suggesting that continuous imiquimod treatment is required for these effects to occur
(Fig 1E).
We next determined whether induction of apoptosis could account for reduced DFTD cell
proliferation in imiquimod treated cultures. We used annexin V and PI staining to measure
the percentage of early, late and total apoptotic cells in the more rapidly responding cell lines
C5065 (DFT1) and RV (DFT2). Our data show a time dependent increase in the percentage of
DFTD cells undergoing apoptosis after imiquimod treatment (Fig 1F). In both cell lines, the
Table 1. Primers designed for RT-PCR.
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
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Fig 1. Imiquimod decreases DFTD cell number in culture in a concentration and time dependent manner. (a) Modulation of relative
cell number in culture by imiquimod treatment was measured using WST-8 assays in DFT1 cell cultures (C5065, 1416, 4906) and a DFT2
Imiquimod-Induced Apoptosis in DFTD
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percentage of cells entering apoptotic pathways peaked at 72 h, with complete apoptosis occur-
ring after 120 h. These data suggest that imiquimod inhibits cell proliferation and subsequently
activates apoptosis in imiquimod treated DFTD cell lines.
Imiquimod regulates the expression of anti-apoptotic genes in DFTD cell
lines
As with other inducers of apoptosis, imiquimod activates apoptotic pathways in tumour cell
lines via regulation of anti-apoptotic genes [15, 20, 35, 36]. To determine whether this occurs
in treated DFTD cultures, we measured the expression of the anti-apoptotic genes BCL2,
BCLXL, MCL1 and A20 at various time points after imiquimod treatment using qRT-PCR. As
DFT1 and DFT2 cell lines responded to imiquimod treatment in a similar manner, they were
grouped together for this analysis. Anti-apoptotic genes had not previously been investigated
in the Tasmanian devil, so we first measured their baseline expression in PBMNCs and periph-
eral nerve, a source of Schwann cells. We compared expression levels to primary DFTD biop-
sies and DFT1 (C5065, 1426, 4906, ½Pea) and DFT2 (RV) cell lines. Relative to 18S rRNA, all
anti-apoptotic genes were expressed at low to moderate levels, and were varied across the
tested tissues (Fig 2A). Expression of anti-apoptotic genes in DFTD primary tumours and cell
lines was within the range of PBMNC and peripheral nerve samples, suggesting that these
genes are not overexpressed beyond normal levels. In response to imiquimod treatment, A20
and MCL1 were significantly up regulated at 24 h, before decreasing as the cells entered apo-
ptosis (Fig 2B). The peak in expression occurred earlier for MCL1 when compared to A20, a
negative regulator of extrinsic apoptosis. Only BCL2 and BCLXL were down regulated signifi-
cantly over the 72 h period. Continuous imiquimod treatment was required for this to occur,
as DFTD cultures treated for only 48 h with imiquimod recovered expression BCL2, BCLXL
and MCL1, but not A20, to levels significantly higher than untreated cultures after the treat-
ment was removed (Fig 2C). Together these data suggest that anti-apoptotic genes play a role
in the regulation of apoptosis in DFTD cells after imiquimod treatment.
Imiquimod regulates the expression of pro-apoptotic genes in DFTD cell
lines
Pro-apoptotic proteins of the BCL2 family have also been implicated in the initiation of
tumour cell death after imiquimod treatment [21]. Genes for BAD, BID, BIM, BAK and BOK
are annotated in the Tasmanian devil genome and were analysed for expression as described
above. As expression of BOK was not detectable in DFTD cultures at any stage of imiquimod
treatment, this gene was not included in the analysis. Relative to 18S rRNA, all pro-apoptotic
genes were expressed at low to moderate levels, and were varied across the tested tissues (Fig
3A). Expression of pro-apoptotic genes in DFTD primary tumours and cell lines was within
the range of both PBMNC and peripheral nerve samples, suggesting that these genes are not
cell culture (RV) treated at the indicated imiquimod concentrations. Cultures were treated with 0.5% DMSO as a vehicle control, which had
no effect. Mean percent relative cell number was calculated by comparison to untreated cultures (b) C5065 DFT1 cultures were treated for
24 or 48 h at the indicated imiquimod concentrations and mean percent relative cell number was calculated by comparison to untreated
cultures using WST-8 assays. (c) DFT1 cultures (C5065, 1416, 4906) and a DFT2 culture (RV) were treated with imiquimod (60 μg/ml)
over a 120 h time course and mean percent relative cell number was calculated by comparison to untreated cultures using WST-8 assays.
Cultures were treated with 0.5% DMSO as a vehicle control, which had no effect. (d) Baseline metabolic rate of C5065, 1426, 4906 and RV
cultures was determined by WST-8 absorbance measures from untreated cells. (e) C5065 cells treated with imiquimod for 24 or 48 h were
washed to remove imiquimod and recovered in culture with no treatment. Mean percent relative cell number was calculated and compared
with a continuously treated culture over 140 h using WST-8 assays. (f) Induction of apoptosis by imiquimod treatment was measured in
C5065 and RV cell lines over a 120 h time course using Annexin V assays. Annexin V (AV) binding identified cells undergoing early and
late apoptosis, while PI staining identified cells in late apoptosis only. All results are the mean and standard error of three replicates.
doi:10.1371/journal.pone.0168068.g001
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Fig 2. Imiquimod modulates the expression of anti-apoptotic genes in DFTD cell lines. (a) Baseline expression. Anti-apoptotic gene expression
was analysed in RNA samples from PBMNC isolates, peripheral nerve samples, primary DFTD biopsies and DFTD cell lines using qRT-PCR. Each
marker represents gene expression level in an individual biological sample or cell line. Results are displayed as the mean and standard error of
expression relative to 18S rRNA. (b) During treatment. Anti-apoptotic gene expression was measured by qRT-PCR in the DFT1 cell lines C5065, 4906
and 1426, and the DFT2 cell line RV, after continuous treatment with imiquimod (60 μg/ml) over a 72 h time course. Box-and-whisker plots represent the
minimum and maximum expression values relative to 18S rRNA, with the upper quartile, median and lower quartile expression values indicated by the
box. (c) After treatment. Anti-apoptotic gene expression was measured by qRT-PCR in the cell lines C5065, 4906, 1426 and RV that were washed after
treatment with imiquimod (60 μg/ml) for 48 h, and recovered for 96 h. Box-and-whisker plots represent the minimum and maximum fold-changes relative
to untreated samples, with the upper quartile, median and lower quartile expression values indicated by the box. Statistical significance compared to the
0 h sample is defined as *<0.05, **<0.01, ***<0.001.
doi:10.1371/journal.pone.0168068.g002
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Fig 3. Imiquimod modulates the expression of pro-apoptotic genes in DFTD cell lines. (a) Baseline expression. Pro-apoptotic gene expression
was analysed in RNA samples from PBMNC isolates, peripheral nerve samples, primary DFTD biopsies and DFTD cell lines using qRT-PCR. Each
marker represents gene expression level in an individual biological sample or cell line. Results are displayed as the mean and standard error of
expression relative to 18S rRNA (b) During treatment. Pro-apoptotic gene expression was measured by qRT-PCR in the DFT1 cell lines C5065, 4906
and 1426, and the DFT2 cell line RV, after continuous treatment with imiquimod (60 μg/ml) over a 72 h time course. Box-and-whisker plots represent the
minimum and maximum expression values relative to 18S rRNA, with the upper quartile, median and lower quartile expression values indicated by the
box. (c) After treatment. Pro-apoptotic gene expression was measured by qRT-PCR in the cell lines C5065, 4906, 1426 and RV that were washed after
treatment with imiquimod (60 μg/ml) for 48 h, and recovered for 96 h. Box-and-whisker plots represent the minimum and maximum fold-changes relative
to untreated samples, with the upper quartile, median and lower quartile expression values indicated by the box. Statistical significance compared to the
0 h sample is defined as *<0.05, **<0.01, ***<0.001.
doi:10.1371/journal.pone.0168068.g003
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abnormally expressed beyond normal levels. In response to imiquimod treatment, expression
of the pro-apoptotic genes BAK and BID remained unchanged, while expression of BAD sig-
nificantly decreased and BIM significantly increased over the 72 h treatment period (Fig 3B).
Cultures treated with imiquimod for only 48 h demonstrated increased expression of BAD,
BAK and BID, and decreased expression of BIM after the treatment was removed. These results
suggest that regulation of pro-apoptotic genes plays a role in apoptosis activated in DFTD cells
after imiquimod treatment.
Expression of TLR7 is absent from DFT1 cell lines
Although imiquimod is an agonist of TLR7, previous studies have shown that it can exert effects
in tumour cells via TLR7-independent mechanisms [13, 18, 37, 38]. To determine whether this is
the case in DFTD, we examined TLR7 expression in DFT1 and DFT2 cell lines. qRT-PCR prod-
ucts from untreated and imiquimod treated cells were visualized by agarose gel electrophoresis
(Fig 4). We found that neither DFT1 nor DFT2 cell lines express detectable levels of TLR7 prior
to or during imiquimod treatment. These results indicate that TLR7 is absent from DFTD cell
lines and does not play a role in the activation of apoptotic pathways after imiquimod treatment.
Imiquimod activates apoptosis in DFTD cells, but not Tasmanian devil
fibroblasts
Previous investigation suggests that imiquimod-induced apoptosis occurs only in tumour cells
[15]. To explore this further, a non-transformed Tasmanian devil fibroblast cell line (TD344)
Fig 4. DFTD cell lines do not express TLR7 after imiquimod treatment. TLR7 expression was measured
in the DFT1 cell line C5065 and DFT2 cell line RV treated with imiquimod (60 μg/ml) over a 72 h time course.
PBMNCs were analysed as a positive control. Extracted RNA was analysed for expression of TLR7 using
qRT-PCR. 18S rRNA was amplified as a reference gene. PCR products were visualized on a 2% agarose gel
with a 100 bp ladder for size comparison.
doi:10.1371/journal.pone.0168068.g004
Imiquimod-Induced Apoptosis in DFTD
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with no detectable expression of TLR7 was treated with imiquimod. We compared the
responses of the fibroblast cell line with DFTD cultures using apoptosis, proliferation and gene
expression assays. Our data show that DFT1 and DFT2 cells, but not fibroblasts, undergo apo-
ptosis after treatment with imiquimod (Fig 5). Co-binding of annexin V and PI demonstrates
a significant difference in the percentage of non-viable cells between untreated and imiqui-
mod-treated samples for DFT1 and DFT2 cell lines (Fig 5A). This trend is not replicated in
fibroblast cultures, suggesting that apoptotic pathways are not activated in these cells. To con-
firm this finding we analysed DNA fragmentation using cell cycle analysis. We detected large
hypodiploid (sub-G1) peaks in imiquimod treated DFT1 and DFT2 cultures, but not fibroblast
cultures, confirming that imiquimod does not activate apoptosis in these cells (Fig 5B). To
understand whether imiquimod had any effect on the growth of Tasmanian devil fibroblasts,
WST-8 assays were performed. High imiquimod concentrations (60 μg/ml) reduced cell num-
ber in fibroblast cultures by around 50% after 48 h of treatment, suggesting that imiquimod
suppresses their growth without activating apoptotic pathways (Fig 5C). Expression analysis of
the pro-apoptotic gene BIM and anti-apoptotic gene BCL2 over a 72 h treatment period
revealed that BCL2 expression was heightened for the treatment duration, while BIM remained
unchanged (Fig 5D). As we previously demonstrated that BCL2 was down regulated and BIM
up regulated by imiquimod treatment in DFTD cells, these results suggest that differential reg-
ulation of pro- and anti- apoptotic proteins plays a role in preventing imiquimod-induced
apoptosis in Tasmanian devil fibroblasts.
Discussion
DFTD continues to threaten the survival of the Tasmanian devil. Efforts to develop a successful
prophylactic vaccine against the disease have produced mixed results, with DFTD-specific
responses generating only short-term disease protection [29]. A successful DFTD therapy
could provide an additional conservation strategy for diseased devils captured during routine
trapping expeditions. Only two previous studies have investigated the use of therapeutic agents
in DFTD. These studies analysed the chemotherapeutic drugs doxorubicin, carboplatin and
vincristine, and found none of these to be effective in the treatment of the DFTD tumour [39,
40]. As DFTD is transmitted as a foreign allograft [26, 22], immunotherapy may be a more
effective treatment strategy, with stimulation of an anti-tumour immune response perhaps suf-
ficient to break immune tolerance and promote regression of the DFTD allograft.
The immunotherapeutic agent imiquimod activates TLR7-dependent immune responses,
resulting in anti-tumour cytotoxicity and tumour regression in human cancers [8–11]. In the
Tasmanian devil, if imiquimod could produce an allogeneic response against DFTD with min-
imal treatments, it would be feasible to opportunistically treat wild diseased devils captured
during routine trapping expeditions with this drug. In human studies imiquimod has also
been shown to directly modulate tumour cells via activation of apoptotic pathways indepen-
dently of TLR7 [13–16, 21, 41]. In vivo, the growth of xenograft tumours in nude mice was
completely suppressed by imiquimod therapy, highlighting roles for imiquimod-induced
effects in the absence of an adaptive response [41]. As such, investigation into the mechanisms
of imiquimod action in DFTD cells could also reveal new strategies for targeting this aggressive
cancer, and could contribute to the development of a successful prophylactic DFTD vaccine.
To gain a better understanding of the effects of imiquimod in DFTD, we performed in vitro
studies, investigating changes to DFT1 and DFT2 tumour cell lines after treatment. Although
DFT1 and DFT2 tumours arose independently [22], both underwent time dependent growth
inhibition and activation of apoptosis after imiquimod treatment. Consistent with previous in
vitro studies, high concentrations were required for the initiation of these effects [13–15, 21].
Imiquimod-Induced Apoptosis in DFTD
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These findings reflect the high amounts of imiquimod required for the immunotherapy of
superficial basal carcinoma in humans, with FDA guidelines suggesting topical application of
Fig 5. Apoptotic pathways are not activated in Tasmanian devil fibroblasts after imiquimod treatment. Cellular responses to
imiquimod treatment were measured in the DFT1 cell line C5065, DFT2 cell line RV and non-transformed fibroblast cell line TD344. (a)
Induction of apoptosis by imquimod was measured through detection of annexin V binding (early and late apoptosis) and PI staining (late
apoptosis and necrosis) after 48 h of imiquimod treatment. (b) DNA fragmentation was measured in fixed cells by flow cytometry analysis of
total DNA staining with PI. A hypodiploid peak represents fragmented DNA and indicates that cells are apoptotic. (c) Modulation of cell
number in C5065 and TD344 cultures by imiquimod treatment was measured using a WST-8 assay. Mean percent relative cell number was
calculated by comparison to untreated cultures. Cells were treated with 0.5% DMSO as a vehicle control, which had no effect. (d)
Expression of pro-apoptotic BIM and anti-apoptotic BCL2 was anaysed in RNA samples from treated fibroblasts using qRT-PCR. Gene
expression levels were measured relative to 18S rRNA. All results are displayed as the mean and standard error of three replicates.
Statistical significance is defined as *<0.05, **<0.01, ***<0.001.
doi:10.1371/journal.pone.0168068.g005
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0.5–2 mg of imiquimod almost daily [42]. It has been suggested that apoptotic pathways in
imiquimod treated tumour cells are activated as a result of ROS accumulation, which enhances
ASK-1 stimulation of JNK and p38 apoptotic pathways [18, 21, 37, 43–45]. Imiquimod-
induced ROS production may occur as a result of calcium induced deregulation of oxidative
phosphorylation [21], and rapid accumulation is likely due to the elevated metabolic activity of
tumour cells. This hypothesis is supported by our results, which show a faster response to imi-
quimod treatment in cell lines with a higher baseline metabolic rate.
The regulation of pro- and anti-apoptotic proteins in imiquimod treated tumour cells has
been well established, with several studies measuring changes to BCL2, MCL1, A20 and Noxa
after treatment [13–15, 20, 21, 35, 41]. Recently, El-Khattouti et al. suggested that localization
of pro-apoptotic Noxa to mitochondria is required for a loss of mitochondrial membrane
potential, cytochrome C release and subsequent apoptosis of imiquimod-treated melanoma
cell lines. Activity of Noxa was controlled through ER-stress mediated activation of PERK sig-
naling and ROS-mediated JNK activation [21]. We were unable to measure Noxa expression
due to incomplete annotation of the Tasmanian devil genome, but we did detect up-regulation
of BIM, a pro-apoptotic protein also activated through ER-stress pathways [46]. This suggests
that similar molecular changes are triggered by imiquimod in DFTD cells. El-Khattouti et al.
hypothesized that ER stress pathways are mediated through TLR7 activation [21], however we
could not detect any expression of TLR7 in our cell lines prior to or after imiquimod treat-
ment. As previous studies have also reported TLR7 independent activation of apoptosis in imi-
quimod treated tumour cell lines [13, 15, 18, 19, 37], we suggest imiquimod induces ER stress
via alternative mechanisms.
The anti-apoptotic genes BCL2,MCL1 and A20 are regulated in tumour cells by imiquimod,
allowing the onset of apoptotic pathways [13, 15, 20, 35]. We detected significant down-regula-
tion of genes encoding BCL2, but not MCL1 or A20. It remains possible that A20 and MCL2
were further down regulated after 72 h of imiquimod treatment, but we were unable to extract
quality RNA to test this due to low cell viability. MCL1 and A20 are involved in suppression of
apoptosis through interactions with Noxa and BIM, and degradation of ASK1, respectively
[47, 48]. We detected transient up regulation of these genes immediately after treatment, sug-
gesting that there may be early activation of pathways protective against Noxa and BIM-medi-
ated apoptosis in response to imiquimod. This could explain both the prolonged survival of
imiquimod treated tumour cells in culture for 96 to 120 h, and the full recovery of imiquimod
pulsed cultures. In vivo, frequent application of imiquimod may be required to overcome these
pathways and induce tumour cell apoptosis. Inhibitors of protective pathways may also have
therapeutic benefit during these treatments by potentiating imiquimod-induced effects.
Human cancer therapies utilize daily topical treatments with imiquimod as a normal practice
[49], but a repetitive protocol of treatment is less feasible in a wild species such as the Tasma-
nian devil. In vivo studies are required to determine whether rejection of the DFTD allograft is
possible in the absence of repetitive treatments.
Although imiquimod is a potent inducer of apoptosis in tumour cells, these effects do not
extend to normal tissues. In vivo, this may restrict imiquimod-induced effects to the tumour
site, preventing substantial damage of surrounding tissue. Our findings align with previous
research where primary keratinocyte cultures were resistant to imiquimod-induced effects, but
treated tumour cells and transformed keratinocyte cultures underwent apoptosis [15]. The
uncontrolled nature of tumour cell growth and metabolism may allow imiquimod-induced
cellular stressors such as ROS to accumulate at a greater rate in these cells, overwhelming
defenses against cellular damage. In addition, neoplastic cells cope with ROS and other stress-
ors at heightened baseline levels relative to normal cells, suggesting that their coping mecha-
nisms may be more easily exhausted by additional stressors [50, 51]. Although imiquimod did
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not activate apoptosis of Tasmanian devil fibroblasts, there was a decrease in cell number after
treatment, suggesting an inhibitory effect on growth. Cell cycle arrest has been documented in
response to imiquimod treatment, and could allow resolution of cellular stress in normal cells
[52]. Aberrations to these mechanisms may lead to the activation of apoptotic pathways in imi-
quimod treated tumour cells.
In summary, we have demonstrated that imiquimod selectively induces apoptosis in DFT1
and DFT2 cell lines. Our results have highlighted the importance of continuous imiquimod
treatment for activation of these pathways, which may have implications for its therapeutic use
in both DFTD and human cancers. As a DFTD immunotherapy, imiquimod has potential to
activate TLR7 mediated immune responses, while deregulating tumour growth and survival in
a direct and targeted manner. Together this suggests that imiquimod is suitable for DFTD
therapy, warranting further investigation into strategies for its use in the Tasmanian devil.
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